GlassScriptPhysician profile
Christina Bonner
NPI 1043238231
$5,520.44
in general payments reported to CMS, 2019-2025
36 companies · $850 in 2025
The $850 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $165 · 2021: $650 · 2022: $1,403 · 2023: $914 · 2024: $852 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.90 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.36 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Organon LLC | $418.70 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $382.29 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $344.04 | 2022-2025 | |
| Hologic Sales and Service, LLC | $241.09 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $219.97 | 2019-2025 | |
| Pfizer INC. | $206.69 | 2023-2025 | |
| Avion Pharmaceuticals | $202.92 | 2021-2023 | Balcoltra |
| Mylan Pharmaceuticals INC. | $190.73 | 2021-2022 | |
| Agile Therapeutics, INC. | $190.32 | 2022-2024 | Twirla |
| Merck Sharp & Dohme LLC | $180.37 | 2019-2024 | Gardasil 9, Gardasil, Vaqta |
| Exeltis, USA INC. | $156.88 | 2024-2025 | Slynd |
| Myovant Sciences INC. | $124.64 | 2022 | |
| Astellas Pharma US INC | $122.02 | 2024-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $107.22 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $96.63 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Biogen, INC. | $86.23 | 2025 | Zurzuvae |
| Allergan, INC. | $84.09 | 2019-2020 | |
| Channel Medsystems, INC. | $78.66 | 2022 | |
| Novo Nordisk INC | $64.76 | 2023-2025 | Wegovy |
| Seqirus USA INC | $63.23 | 2024-2025 | Flucelvax, Fluad |
| Exact Sciences Corporation | $60.65 | 2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $58.95 | 2022-2023 | Bd Onclarity |
| Therapeuticsmd, INC. | $56.62 | 2019-2020 | |
| Gynesonics, INC. | $37.99 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Dysis Medical, INC. | $37.02 | 2019-2022 | |
| Amgen INC. | $36.82 | 2024 | Evenity, Prolia |
| Vertical Pharmaceuticals, LLC | $36.02 | 2019 | |
| Lupin INC. | $32.21 | 2019 | |
| Boston Scientific Corporation | $29.92 | 2019 | |
| Sumitomo Pharma America, INC. | $26.93 | 2023 | Myfembree |
| Mission Pharmacal Company | $24.93 | 2019 | |
| Scynexis, INC. | $21.07 | 2022 | |
| Sanofi Pasteur INC. | $20.89 | 2024 | |
| Monaghan Medical Corporation | $16.96 | 2023 | Aerobika |
| Duchesnay USA Incorporated | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.